ChargePoint Technology Industry Blog
A significant amount of time and money is invested in your process equipment to protect your employees and maximise the quality of high value ingredients and formulations. You also invest a lot of resources into the regular maintenance of critical equipment, such as replacement of filters and seals in isolators, air locks and cleanroom HVAC- But do you invest enough time and pay the same attention to maintaining your split butterfly valves?
The industry is currently seeing a sharp increase in demand for high potency active pharmaceutical ingredients (HPAPIs). This means that many manufacturers are considering which containment strategies will work well for them and meet their high potency handling requirements.
In his latest article for EPM Magazine, our global product manager Michael Avraam highlights the evolution of containment strategies, and analyses the role of containment verification and monitoring. Read the article in full here.
If manufacturing environments are not properly controlled, they may be left open to many sources of potential contamination. This is why pharma companies are looking into techniques that can be used to make their working environments safe. Our global product manager, Christian Dunne, has highlighted the key approaches to sterile manufacturing and the advantages they can bring. From aseptic isolators, to restricted access barrier systems, he has offered a comprehensive overview of each technique. Read the full article on page 72 here.
As more pharmaceutical businesses focus on creating innovative, targeted therapies, the industry is having to adapt like never before. Contamination control in particular has advanced and developed significantly.
Global product manager, Michael Avraam, discusses how businesses are transforming their approaches to containment and the safe development of pharmaceutical products in an article for Pharmaceutical Manufacturing.
A growing demand for highly potent active pharmaceutical ingredients (HPAPIs), twinned with the prevalence of oncological, immunosuppressant and hormone-based products is fuelling need for high potency handling capabilities.
ChargePoint Technology's very own Michael Avraam discusses the potential issues with containment performance testing, data collection and interpretation and how these may affect end user with Pharma Focus Asia. You can read the full article (pg.50) here.